Couverture de Off the Scales

Off the Scales

The Inside Story of Ozempic and the Race to Cure Obesity

OFFRE D'UNE DURÉE LIMITÉE

3 mois gratuits
Précommander pour 0,00 €
Cette offre est valable du 17.06.2025 au 31.07.2025.
1 livre audio par mois au choix dans notre catalogue inégalé.
Écoutez des milliers de livres audio, podcasts et Audible Originals.
Après 3 mois, 9,95 €/mois.

Off the Scales

De : Aimee Donnellan
Lu par : Yael Rizowy
Précommander pour 0,00 €

Après 3 mois, 9,95 €/mois. Cette offre est valable du 17.06.2025 au 31.07.2025. Résiliez à tout moment.

Précommander pour 18,66 €

Précommander pour 18,66 €

Confirmer la précommande
Utiliser la carte qui se termine par
En finalisant votre achat, vous acceptez les Conditions d'Utilisation. Veuillez prendre connaissance de notre Politique de Confidentialité et de notre Politique sur la Publicité et les Cookies.
Annuler

À propos de cette écoute

The inside story of the race to develop Ozempic, and its potentially revolutionary impact on public health and culture.

A “cure” for obesity has long been the holy grail for the pharmaceutical industry, one that seemed unattainable until recent breakthroughs in type 2 diabetes research led to the development of Ozempic, a weight loss medication that activates hormones in the stomach, making people feel fuller for longer. The treatment is so effective that it is already disrupting many industries—from healthcare to fast food to fashion—and it has quickly made its creator, Denmark’s Novo Nordisk, the most valuable company in Europe. But the impact of these drugs goes far beyond billion-dollar profits; a true long-term cure for obesity could save 40% of American adults from dangerous preventable illnesses. And as their success continues to grow, one question looms in the minds of investors, healthcare workers and politicians: are they too good to be true?

In Off the Scales, Reuters journalist Aimee Donnellan illuminates the history of the latest medical breakthrough that is poised to change the world, while bringing difficult social questions about inequality and morality to the forefront. Through original reporting and rigorous research, she forecasts the future of Ozempic and similar medications—and examines what their explosive popularity tells us about our ideals of beauty, the lengths to which people will go in order to become thin, the current state of healthcare, and the inner workings of the pharmaceutical industry.

Along the way, Donnellan profiles the scientist whose contributions to the discovery of GLP-1 were overlooked and her fight for recognition while her colleagues were thrust into the limelight, and offers new insights into the ways that the food and beauty industries made billions while promoting unhealthy and unrealistic body image standards and accelerating the obesity crisis. She also reveals the lengths that the celebrity class went to obtain this medication when supplies were limited and prescriptions were costly, and relates the first-hand accounts of several early Ozempic users and the transformative effect the drug has had on their weight loss journeys. Above all, Off the Scales is an informative and entertaining study of the unexpected social consequences of finally getting what we've wanted for so long.

©2025 Aimee Donnellan (P)2025 Macmillan Audio
Fitness, alimentation et nutrition Médecine et secteur des soins de santé Perte de poids et contrôle du poids Régimes, nutrition et alimentation saine
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !

    Ce que les auditeurs disent de Off the Scales

    Moyenne des évaluations utilisateurs. Seuls les utilisateurs ayant écouté le titre peuvent laisser une évaluation.

    Commentaires - Veuillez sélectionner les onglets ci-dessous pour changer la provenance des commentaires.

    Il n'y a pas encore de critique disponible pour ce titre.